Combined estimates and sensitivity analyses for each of the groups
| Cancer and drug | Studies | Combined risk estimate (95% CI) |
|---|---|---|
| Esophageal cancer and all bisphosphonates—main analysis | Vestergaard-DNR, Vinogradova-CPRD, Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD | 1.11 (0.97 to 1.27) |
| Sensitivity analysis (1) | Vestergaard-DNR, Wright-CPRD, Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD | 1.29 (0.97 to 1.72) |
| Sensitivity analysis (2) | Vestergaard-DNR, Green-CPRD, Vinogradova-QRes, Chen-NHICD, Nguyen-VAD | 1.11 (0.95 to 1.29) |
| Sensitivity analysis (3) | Vestergaard-DNR, Cardwell-CPRD, Vinogradova-QRes, Lee-NHICD, Nguyen-VAD | 1.03 (0.88 to 1.22) |
| Gastric cancer and all bisphosphonates | Vestergaard-DNR, Vinogradova-CPRD, Vinogradova-QRes, Chiang-NHICD | 0.96 (0.82 to 1.12) |
| Esophageal cancer and alendronate—main analysis | Abrahamsen-DNR, Vinogradova-CPRD, Vinogradova-QRes, Chiang-NHICD, Nguyen-VAD | 0.98 (0.87 to 1.11) |
| Sensitivity analysis (1) | Abrahamsen-DNR, Wright-CPRD, Vinogradova-QRes, Chen-NHICD, Nguyen-VAD | 0.97 (0.70 to 1.34) |
| Sensitivity analysis (2) | Abrahamsen-DNR, Cardwell-CPRD, Vinogradova-QRes, Chen-NHICD, Nguyen-VAD | 0.85 (0.71 to 1.02) |
| Sensitivity analysis (3) | Abrahamsen-DNR, Cardwell-CPRD, Vinogradova-QRes, Lee-NHICD, Nguyen-VAD | 0.86 (0.72 to 1.04) |
| Gastric cancer and alendronate | Abrahamsen-DNR, Chiang-NHICD, Vinogradova-QRes, Vinogradova-CPRD | 0.99 (0.71 to 1.38) |
| Upper GI cancer and all bisphosphonates | Cohort studies: Vestergaard-DNR, Cardwell-CPRD, Chiang-NHICD | 1.32 (0.81 to 2.13) |
| Upper GI cancer and all bisphosphonates | Case control studies: Vinogradova-CPRD, Vinogradova-QRes, Nguyen-VAD, Chen-NHICD | 1.06 (0.93 to 1.22) |
CPRD, Clinical Practice Research Data Link Database; DNR, Danish National Registries; GI, gastrointestinal; NHICD, National Health Insurance Claims Database; Qres, Q-Research; VAD, Veterans Affairs Database.